Top

Published in:

01-12-2011 | Otitis (David P. Skoner, Section Editor)

Innate Immunity and the Role of Defensins in Otitis Media

Authors: Mark Underwood, Lauren Bakaletz

Published in: Current Allergy and Asthma Reports | Issue 6/2011

Abstract

Otitis media is the most common pediatric disease in developed countries and a significant cause of morbidity and hearing loss in developing countries. The innate immune system is essential to protecting the middle ear from infection. Defensins, broad-spectrum cationic antimicrobial peptides, have been implicated in prevention of and the early response to acute otitis media; however, the mechanisms by which defensins and other antimicrobial molecules mediate this protection have not been completely elucidated. In both animal otitis media models and human middle ear epithelial cell culture models, β-defensins are highly induced and effectively kill the common pathogens associated with otitis media. We review the importance of innate immunity in protecting the middle ear and recent advances in understanding the roles of defensins and other antimicrobial molecules in the prevention and treatment of otitis media. The extremely high prevalence of otitis media, in spite of sophisticated innate and adaptive immune systems, is a vexing problem for clinicians and scientists. We therefore also review mechanisms by which bacteria evade innate immune defenses.

Taylor PS, Faeth I, Marks MK, Del Mar CB, Skull SA, Pezzullo ML, et al. Cost of treating otitis media in Australia. Expert Rev Pharmacoecon Outcomes Res. 2009;9:133–41.PubMedCrossRef

Coyte PC, Asche CV, Elden LM. The economic cost of otitis media in Canada. Int J Pediatr Otorhinolaryngol. 1999;49:27–36.PubMedCrossRef

O’Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, et al. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics. 2009;123:1452–63.PubMedCrossRef

Kalu SU, Ataya RS, McCormick DP, Patel JA, Revai K, Chonmaitree T. Clinical spectrum of acute otitis media complicating upper respiratory tract viral infection. Pediatr Infect Dis J. 2011;30:95–9.PubMedCrossRef

Post JC, Hiller NL, Nistico L, Stoodley P, Ehrlich GD. The role of biofilms in otolaryngologic infections: update 2007. Curr Opin Otolaryngol Head Neck Surg. 2007;15:347–51.PubMedCrossRef

• Hoa M, Syamal M, Schaeffer MA, Sachdeva L, Berk R, Coticchia J. Biofilms and chronic otitis media: an initial exploration into the role of biofilms in the pathogenesis of chronic otitis media. Am J Otolaryngol. 2010;31:241–5. Analysis of biofilms on adenoidal tissue removed from children with recurrent OM, OM with effusion, and sleep apnea showed marked differences. Biofilm formation was extensive in recurrent OM, moderate in OM with effusion, and minimal in sleep apnea. This suggests a significant role of biofilms in recurrent OM.PubMedCrossRef

• Murphy TF, Bakaletz LO, Smeesters PR. Microbial interactions in the respiratory tract. Pediatr Infect Dis J. 2009;28:S121–6. This article summarizes the interactions and competition between the major pathogens of OM and the importance of biofilm formation in chronic OM. PubMedCrossRef

Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics. 2006;117:1823–9.PubMedCrossRef

Kaur R, Adlowitz DG, Casey JR, Zeng M, Pichichero ME. Simultaneous assay for four bacterial species including Alloiococcus otitidis using multiplex-PCR in children with culture negative acute otitis media. Pediatr Infect Dis J. 2010;29:741–5.PubMedCrossRef

10.

De Baere T, Vaneechoutte M, Deschaght P, Huyghe J, Dhooge I. The prevalence of middle ear pathogens in the outer ear canal and the nasopharyngeal cavity of healthy young adults. Clin Microbiol Infect. 2010;16:1031–5.PubMed

11.

Paluch-Oles J, Magrys A, Koziol-Montewka M, Niedzielski A, Niedzwiadek J, Niedzielska G, et al. The phenotypic and genetic biofilm formation characteristics of coagulase-negative staphylococci isolates in children with otitis media. Int J Pediatr Otorhinolaryngol. 2010;75:126–30.PubMedCrossRef

12.

Kaji C, Watanabe K, Apicella MA, Watanabe H. Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms. Tohoku J Exp Med. 2008;214:121–8.PubMedCrossRef

13.

Lee SK, Lee MS, Jung SY, Byun JY, Park MS, Yeo SG. Antimicrobial resistance of Pseudomonas aeruginosa from otorrhea of chronic suppurative otitis media patients. Otolaryngol Head Neck Surg. 2010;143:500–5.PubMedCrossRef

14.

• Shim HJ, Park CH, Kim MG, Lee SK, Yeo SG. A pre- and postoperative bacteriological study of chronic suppurative otitis media. Infection. 2010;38:447–52. This was a survey of the microbiota in chronic suppurative otitis before and after surgery. The major organisms were S. aureus, coagulase-negative staphylococci, and P. aeruginosa, with the latter most likely to persist after surgery. PubMedCrossRef

15.

Ricciardiello F, Cavaliere M, Mesolella M, Iengo M. Notes on the microbiology of cholesteatoma: clinical findings and treatment. Acta Otorhinolaryngol Ital. 2009;29:197–202.PubMed

16.

American Academy of Pediatrics SoMoAOM. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451–65.CrossRef

17.

American Academy of Pediatrics SoOMwE. Otitis media with effusion. Pediatrics. 2004;113:1412–29.CrossRef

18.

• Coco A, Vernacchio L, Horst M, Anderson A. Management of acute otitis media after publication of the 2004 AAP and AAFP clinical practice guideline. Pediatrics. 2010;125:214–20. This was a comparison of treatment of otitis in the United States for the 30 months before and the 30 months after publication of the 2004 guidelines. There was no significant change in the number of patients with otitis who were not treated with antibiotics, but there was an increase in use of amoxicillin and a decrease in use of amoxicillin-clavulanate. PubMedCrossRef

19.

Vergison A, Dagan R, Arguedas A, Bonhoeffer J, Cohen R, Dhooge I, et al. Otitis media and its consequences: beyond the earache. Lancet Infect Dis. 2010;10:195–203.PubMedCrossRef

20.

Leichtle A, Lai Y, Wollenberg B, Wasserman SI, Ryan AF. Innate signaling in otitis media: pathogenesis and recovery. Curr Allergy Asthma Rep. 2011;11:78–84.PubMedCrossRef

21.

Hernandez M, Leichtle A, Pak K, Ebmeyer J, Euteneuer S, Obonyo M, et al. Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. J Infect Dis. 2008;198:1862–9.PubMedCrossRef

22.

•• Leichtle A, Hernandez M, Pak K, Yamasaki K, Cheng CF, Webster NJ, et al. TLR4-mediated induction of TLR2 signaling is critical in the pathogenesis and resolution of otitis media. Innate Immun. 2009;15:205–15. This article describes inflammatory responses to NTHI in wild-type, TLR2 knockout, and TLR4 knockout mice. Both knockout groups demonstrated decreased tumor necrosis factor induction, delayed bacterial clearance, and persistent inflammation compared with wild-type mice. TLR2 induction was decreased in the TLR4 knockouts, suggesting that TLR4 induces TLR2 expression; both receptors are important in the immune response to NTHI. PubMedCrossRef

23.

•• Leichtle A, Hernandez M, Lee J, Pak K, Webster NJ, Wollenberg B, et al. The role of DNA sensing and innate immune receptor TLR9 in otitis media. Innate Immun. 2011. TLR9 senses bacterial DNA. TLR9 knockout mice demonstrate delayed bacterial clearance and persistent inflammation after middle ear infection with NTHI compared with wild-type mice. TLR9 is also important in the immune response to NTHI.

24.

Dalia AB, Standish AJ, Weiser JN. Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun. 2010;78:2108–16.PubMedCrossRef

25.

Juneau RA, Pang B, Weimer KE, Armbruster CE, Swords WE. Nontypeable Haemophilus influenzae initiates formation of neutrophil extracellular traps. Infect Immun. 2011;79:431–8.PubMedCrossRef

26.

•• Hirano T, Kodama S, Moriyama M, Kawano T, Suzuki M. The role of Toll-like receptor 4 in eliciting acquired immune responses against nontypeable Haemophilus influenzae following intranasal immunization with outer membrane protein. Int J Pediatr Otorhinolaryngol. 2009;73:1657–65. Outer membrane proteins of NTHI are promising vaccine candidates. Comparison of mucosal and systemic immune responses to intranasal instillation of NTHI outer membrane proteins in wild-type and TLR4 knockout mice demonstrated the importance of the TLR4 receptor in response to this potential vaccine. PubMedCrossRef

27.

Takahashi N, Yamada T, Narita N, Fujieda S. Double-stranded RNA induces production of RANTES and IL-8 by human nasal fibroblasts. Clin Immunol. 2006;118:51–8.PubMedCrossRef

28.

Oliver BG, Johnston SL, Baraket M, Burgess JK, King NJ, Roth M, et al. Increased proinflammatory responses from asthmatic human airway smooth muscle cells in response to rhinovirus infection. Respir Res. 2006;7:71.PubMedCrossRef

29.

Nonaka M, Ogihara N, Fukumoto A, Sakanushi A, Pawankar R, Yagi T. Poly(I:C) synergizes with Th2 cytokines to induce TARC/CCL17 in middle ear fibroblasts established from mucosa of otitis media with effusion. Acta Otolaryngol Suppl. 2009;57–62.

30.

Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. 2010;11:76–83.PubMedCrossRef

31.

Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol. 2007;19:70–83.PubMedCrossRef

32.

Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–20.PubMedCrossRef

33.

Lehrer RI. Primate defensins. Nat Rev Microbiol. 2004;2:727–38.PubMedCrossRef

34.

Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389–95.PubMedCrossRef

35.

Lehrer RI, Jung G, Ruchala P, Wang W, Micewicz ED, Waring AJ, et al. Human alpha-defensins inhibit hemolysis mediated by cholesterol-dependent cytolysins. Infect Immun. 2009;77:4028–40.PubMedCrossRef

36.

Yang D, Liu ZH, Tewary P, Chen Q, de la Rosa G, Oppenheim JJ. Defensin participation in innate and adaptive immunity. Curr Pharm Des. 2007;13:3131–9.PubMedCrossRef

37.

• Bakaletz LO. Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention. Expert Rev Vaccines. 2009;8:1063–82. This article presents a description of the chinchilla as the gold standard for polymicrobial OM. PubMedCrossRef

38.

Harris RH, Wilk D, Bevins CL, Munson Jr RS, Bakaletz LO. Identification and characterization of a mucosal antimicrobial peptide expressed by the chinchilla (Chinchilla lanigera) airway. J Biol Chem. 2004;279:20250–6.PubMedCrossRef

39.

McGillivary G, Ray WC, Bevins CL, Munson Jr RS, Bakaletz LO. A member of the cathelicidin family of antimicrobial peptides is produced in the upper airway of the chinchilla and its mRNA expression is altered by common viral and bacterial co-pathogens of otitis media. Mol Immunol. 2007;44:2446–58.PubMedCrossRef

40.

•• McGillivary G, Mason KM, Jurcisek JA, Peeples ME, Bakaletz LO. Respiratory syncytial virus-induced dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway by non-typeable Haemophilus influenzae. Cell Microbiol. 2009;11:1399–408. This study demonstrated an important mechanism underlying polymicrobial OM. Infection with RSV inhibits chinchilla β-defensin expression, thereby allowing NTHI to flourish. PubMedCrossRef

41.

Jin Shin D, Gan-Undram S, Jin Kim S, Joon Jun Y, Jung Im G, Hyun Jung H. Expression of beta-defensins in the tubotympanum of experimental otitis media. Acta Otolaryngol. 2006;126:1040–5.PubMedCrossRef

42.

Jiang Y, Wang Y, Wang B, Yang D, Yu K, Yang X, et al. Antifungal activity of recombinant mouse beta-defensin 3. Lett Appl Microbiol. 2010;50:468–73.PubMedCrossRef

43.

• Gong T, Jiang Y, Wang Y, Yang D, Li W, Zhang Q, et al. Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry. Arch Virol. 2010;155:491–8. Mouse β-defensin 2 has strong antiviral activity against influenza A and is protective in mice when administered before or immediately after a lethal dose of influenza A. PubMedCrossRef

44.

Lee HY, Andalibi A, Webster P, Moon SK, Teufert K, Kang SH, et al. Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect Dis. 2004;4:12.PubMedCrossRef

45.

Moon SK, Lee HY, Pan H, Takeshita T, Park R, Cha K, et al. Synergistic effect of interleukin 1 alpha on nontypeable Haemophilus influenzae-induced up-regulation of human beta-defensin 2 in middle ear epithelial cells. BMC Infect Dis. 2006;6:12.PubMedCrossRef

46.

Lee HY, Takeshita T, Shimada J, Akopyan A, Woo JI, Pan H, et al. Induction of beta defensin 2 by NTHi requires TLR2 mediated MyD88 and IRAK-TRAF6-p38MAPK signaling pathway in human middle ear epithelial cells. BMC Infect Dis. 2008;8:87.PubMedCrossRef

47.

Bishop-Hurley SL, Schmidt FJ, Erwin AL, Smith AL. Peptides selected for binding to a virulent strain of Haemophilus influenzae by phage display are bactericidal. Antimicrob Agents Chemother. 2005;49:2972–8.PubMedCrossRef

48.

Alzbutiene G, Hermansson A, Caye-Thomasen P, Kinduris V. Tympanic membrane changes in experimental acute otitis media and myringotomy. Medicina (Kaunas). 2008;44:313–21.

49.

Vonk MJ, Hiemstra PS, Grote JJ. An antimicrobial peptide modulates epithelial responses to bacterial products. Laryngoscope. 2008;118:816–20.PubMedCrossRef

50.

Shimada J, Moon SK, Lee HY, Takeshita T, Pan H, Woo JI, et al. Lysozyme M deficiency leads to an increased susceptibility to Streptococcus pneumoniae-induced otitis media. BMC Infect Dis. 2008;8:134.PubMedCrossRef

51.

• Wescombe PA, Heng NC, Burton JP, Chilcott CN, Tagg JR. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol. 2009;4:819–35. This article describes the diverse bacteriocins produced by streptococci. Special emphasis is placed on a promising commensal strain that produces broad-spectrum bacteriocins. PubMedCrossRef

52.

Roos K, Hakansson EG, Holm S. Effect of recolonisation with “interfering” alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ. 2001;322:210–2.PubMedCrossRef

53.

Brook I. The role of bacterial interference in otitis, sinusitis and tonsillitis. Otolaryngol Head Neck Surg. 2005;133:139–46.PubMedCrossRef

54.

Knoetze H, Todorov SD, Dicks LM. A class IIa peptide from Enterococcus mundtii inhibits bacteria associated with otitis media. Int J Antimicrob Agents. 2008;31:228–34.PubMedCrossRef

55.

• Jang CH, Cho YB, Oh SE, Choi JU, Park H, Choi CH. Effect of nebulized bovine surfactant for experimental otitis media with effusion. Clin Exp Otorhinolaryngol. 2010;3:13–7. This article explores the novel approach of using nebulized bovine surfactant to reduce eustachian tube opening pressure in a guinea pig model of OM with effusion. PubMedCrossRef

56.

• McGillivary G, Bakaletz LO. The multifunctional host defense peptide SPLUNC1 is critical for homeostasis of the mammalian upper airway. PLoS One. 2010;5:e13224. This study demonstrated the role of the antimicrobial peptide SLPUNC1 in maintaining efficient mucociliary middle ear clearance in the chinchilla model of OM. PubMedCrossRef

57.

Jang WS, Kim KN, Lee YS, Nam MH, Lee IH. Halocidin: a new antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium. FEBS Lett. 2002;521:81–6.PubMedCrossRef

58.

• Lee YS, Kim YJ, Choi SH, Shin KH, Jang WS, Lee IH, et al. Di-K19Hc, an antimicrobial peptide as new ototopical agent for treatment of otitis media. Acta Otolaryngol. 2010;130:897–903. This study demonstrated strong antibacterial activity of a synthetic halocidin against multiple drug-resistant strains of P. aeruginosa and methicillin-resistant S. aureus. PubMedCrossRef

59.

• Kurola P, Tapiainen T, Sevander J, Kaijalainen T, Leinonen M, Uhari M, et al. Effect of xylitol and other carbon sources on Streptococcus pneumoniae biofilm formation and gene expression in vitro. Apmis. 2010;119:135–42. Twenty pneumococcal isolates obtained from middle ear aspirates were grown in culture media containing xylitol, glucose, fructose, or combinations of these sugars. Xylitol inhibited bacterial growth and biofilm formation, but glucose and fructose (alone or added to xylitol) had the opposite effect. PubMedCrossRef

60.

Uhari M, Kontiokari T, Niemela M. A novel use of xylitol sugar in preventing acute otitis media. Pediatrics. 1998;102:879–84.PubMedCrossRef

61.

Taipale T, Pienihakkinen K, Alanen P, Jokela J, Soderling E. Dissolution of xylitol from a food supplement administered with a novel slow-release pacifier: preliminary results. Eur Arch Paediatr Dent. 2007;8:123–5.PubMed

62.

Mason KM, Munson Jr RS, Bakaletz LO. A mutation in the sap operon attenuates survival of nontypeable Haemophilus influenzae in a chinchilla model of otitis media. Infect Immun. 2005;73:599–608.PubMedCrossRef

63.

Mason KM, Bruggeman ME, Munson RS, Bakaletz LO. The non-typeable Haemophilus influenzae Sap transporter provides a mechanism of antimicrobial peptide resistance and SapD-dependent potassium acquisition. Mol Microbiol. 2006;62:1357–72.PubMedCrossRef

64.

Roy H, Dare K, Ibba M. Adaptation of the bacterial membrane to changing environments using aminoacylated phospholipids. Mol Microbiol. 2009;71:547–50.PubMedCrossRef

65.

• Haggard M. Poor adherence to antibiotic prescribing guidelines in acute otitis media—obstacles, implications, and possible solutions. Eur J Pediatr. 2011;170:323–32. This article reviews treatment guidelines from several organizations, barriers to compliance with these guidelines, and recommendations for improvement. PubMedCrossRef

66.

Murphy TF. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines. 2005;4:843–53.PubMedCrossRef

67.

Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother. 2005;49:269–75.PubMedCrossRef

68.

Soehnlein O, Kai-Larsen Y, Frithiof R, Sorensen OE, Kenne E, Scharffetter-Kochanek K, et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest. 2008;118:3491–502.PubMedCrossRef

69.

Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods. 2006;65:335–45.PubMedCrossRef

70.

Diamond G, Ryan L. Beta-defensins: what are they REALLY doing in the oral cavity? Oral Dis. 2011 Feb 18 (Epub ahead of print).

71.

Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30:131–41.PubMedCrossRef

72.

Ibrahim HR, Thomas U, Pellegrini A. A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J Biol Chem. 2001;276:43767–74.PubMedCrossRef

73.

Jang WS, Kim HK, Lee KY, Kim SA, Han YS, Lee IH. Antifungal activity of synthetic peptide derived from halocidin, antimicrobial peptide from the tunicate, Halocynthia aurantium. FEBS Lett. 2006;580:1490–6.PubMedCrossRef

Title: Innate Immunity and the Role of Defensins in Otitis Media
Authors: Mark Underwood
Lauren Bakaletz
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Allergy and Asthma Reports / Issue 6/2011
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-011-0223-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Innate Immunity and the Role of Defensins in Otitis Media

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Overview of Serological-Specific IgE Antibody Testing in Children

Reassessing the Evidence Hierarchy in Asthma: Evaluating Comparative Effectiveness

Spacers and Valved Holding Chambers in Asthma Drug Delivery: How Many Breaths Are Needed to Achieve Adequate Lung Deposition?

Medication Adherence in the Asthmatic Child and Adolescent

Should Newborns be Screened for Immunodeficiency? Lessons Learned from Infants with Recurrent Otitis Media

Oral Food Challenges in Children: Review and Future Perspectives